uniQure (NASDAQ:QURE) Earns Buy Rating from Chardan Capital

Chardan Capital reissued their buy rating on shares of uniQure (NASDAQ:QURE - Free Report) in a research note released on Monday,Benzinga reports. The firm currently has a $38.00 price objective on the biotechnology company's stock. Chardan Capital also issued estimates for uniQure's FY2025 earnings at ($4.04) EPS and FY2026 earnings at ($3.20) EPS.

A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Monday, April 21st. StockNews.com raised uniQure to a "sell" rating in a report on Tuesday, March 11th. Royal Bank of Canada reissued an "outperform" rating and set a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Finally, Wells Fargo & Company reduced their target price on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, uniQure has a consensus rating of "Moderate Buy" and an average price target of $37.82.

uniQure Stock Performance

NASDAQ QURE traded up $0.45 on Monday, reaching $13.70. The stock had a trading volume of 1,614,113 shares, compared to its average volume of 1,877,379. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a fifty day moving average of $12.31 and a two-hundred day moving average of $12.28. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a market cap of $750.43 million, a P/E ratio of -2.76 and a beta of 0.10.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. The firm had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. On average, equities research analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares in the company, valued at approximately $1,756,501.76. This trade represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 28,341 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares of the company's stock, valued at $6,703,461.66. This trade represents a 4.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock valued at $961,401 over the last ninety days. 4.74% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Hedge funds have recently made changes to their positions in the stock. Twin Tree Management LP bought a new stake in uniQure in the fourth quarter worth approximately $77,000. FNY Investment Advisers LLC purchased a new position in shares of uniQure during the fourth quarter valued at approximately $88,000. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure during the first quarter valued at approximately $106,000. OMERS ADMINISTRATION Corp bought a new position in uniQure in the 1st quarter valued at $152,000. Finally, ADAR1 Capital Management LLC bought a new position in uniQure in the 4th quarter valued at $177,000. 78.83% of the stock is currently owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.